Education
About Us
Working with TipRanks
Follow Us
BeOne Medicines Ltd (HK:6160)
:6160
6160 Stock Chart & Stats
HK$214.40
HK$5.50(5.26%)
At close: 4:00 PM EST
HK$214.40
HK$5.50(5.26%)
Day’s Range― - ―
52-Week RangeHK$115.80 - HK$229.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)5.08M
Market Cap
HK$330.32B
Enterprise ValueHK$36.83B
Total Cash (Recent Filing)HK$4.04B
Total Debt (Recent Filing)HK$1.02B
Price to Earnings (P/E)661.7
Beta1.03
Next Earnings
Feb 26, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding1,540,976,000
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)5.77
Price to Sales (P/S)5.05
P/FCF Ratio-28.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$255.33Price Target Upside19.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe strong revenue growth rate indicates a positive trajectory in sales, suggesting the company's products are gaining market traction, which could lead to sustained financial performance.
Cash Flow ImprovementSignificant improvement in cash flow generation enhances financial flexibility, allowing for strategic investments and reducing reliance on external financing.
Strong Gross Profit MarginA high gross profit margin reflects efficient cost management, which supports profitability and allows for reinvestment in R&D and market expansion.
Bears Say
Profitability ChallengesDespite revenue growth, the company struggles to convert sales into profits, which may hinder its ability to reinvest in growth and innovation.
Negative Return On EquityA negative return on equity indicates challenges in generating returns for shareholders, potentially impacting investor confidence and long-term capital raising.
High Valuation RiskAn extremely high P/E ratio suggests the stock is priced for significant growth, which could be risky if growth expectations are not met, impacting long-term investor sentiment.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$115.80 and its highest was HK$229.40 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$330.32B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 2 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on Nov 06, 2025. The company reported HK$0.652 earnings per share for the quarter, beating the consensus estimate of HK$0.544 by HK$0.108.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 0.77.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,540,976,000 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$0.652 in its last earnings report, beating expectations of HK$0.544. Following the earnings report the stock price went up 1.616%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
-4.94%
Trailing 12-Months
Asset Growth
10.86%
Trailing 12-Months
Company Description
BeOne Medicines Ltd
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
6160 Stock 12 Month Forecast
Average Price Target
HK$255.33
▲(19.09% Upside)
Technical Analysis
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
WuXi AppTec Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
―
Options Prices
Currently, No data available
---